Atreca Inc IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Atreca Inc | BCEL - NASDAQ |
$16.00-$18.00 | $17.00 | $19.90 | 7.4 million | 6/20/2019 |
| Cowen, Evercore ISI, Stifel | ||||||
Co-Manager(s): Canaccord Genuity, Brookline Capital | ||||||
| Health Care | ||||||
Filing(s): FIled 2019-05-24 Terms Added 2019-06-10 | ||||||
Atreca Inc Quote & Chart - Click for current quote - BCEL
IPO Boutique aggregates information on public companies and private companies, such as "BCEL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Atreca Inc (adapted from Atreca Inc prospectus):
They are a biopharmaceutical company utilizing our differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a biopharmaceutical company utilizing our differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "BCEL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.